![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BNC1 |
Gene summary for BNC1 |
![]() |
Gene information | Species | Human | Gene symbol | BNC1 | Gene ID | 646 |
Gene name | basonuclin 1 | |
Gene Alias | BNC | |
Cytomap | 15q25.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B7Z885 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
646 | BNC1 | CCI_1 | Human | Cervix | CC | 2.18e-05 | 5.99e-01 | 0.528 |
646 | BNC1 | CCI_2 | Human | Cervix | CC | 2.82e-10 | 8.57e-01 | 0.5249 |
646 | BNC1 | CCI_3 | Human | Cervix | CC | 1.58e-05 | 4.18e-01 | 0.516 |
646 | BNC1 | Tumor | Human | Cervix | CC | 2.08e-06 | 2.54e-01 | 0.1241 |
646 | BNC1 | sample3 | Human | Cervix | CC | 1.39e-06 | 2.34e-01 | 0.1387 |
646 | BNC1 | T3 | Human | Cervix | CC | 1.42e-08 | 2.56e-01 | 0.1389 |
646 | BNC1 | C04 | Human | Oral cavity | OSCC | 9.50e-21 | 1.02e+00 | 0.2633 |
646 | BNC1 | C21 | Human | Oral cavity | OSCC | 6.29e-18 | 4.71e-01 | 0.2678 |
646 | BNC1 | C30 | Human | Oral cavity | OSCC | 1.75e-30 | 1.07e+00 | 0.3055 |
646 | BNC1 | C43 | Human | Oral cavity | OSCC | 7.76e-06 | 1.25e-01 | 0.1704 |
646 | BNC1 | C46 | Human | Oral cavity | OSCC | 1.10e-03 | 1.27e-01 | 0.1673 |
646 | BNC1 | C51 | Human | Oral cavity | OSCC | 1.48e-21 | 9.02e-01 | 0.2674 |
646 | BNC1 | C57 | Human | Oral cavity | OSCC | 2.05e-02 | 1.54e-01 | 0.1679 |
646 | BNC1 | C06 | Human | Oral cavity | OSCC | 4.71e-06 | 1.02e+00 | 0.2699 |
646 | BNC1 | C08 | Human | Oral cavity | OSCC | 3.75e-04 | 1.67e-01 | 0.1919 |
646 | BNC1 | LN22 | Human | Oral cavity | OSCC | 9.08e-08 | 8.28e-01 | 0.1733 |
646 | BNC1 | LP15 | Human | Oral cavity | LP | 5.18e-03 | 4.68e-01 | 0.2174 |
646 | BNC1 | LP17 | Human | Oral cavity | LP | 8.12e-03 | 4.72e-01 | 0.2349 |
646 | BNC1 | SYSMH1 | Human | Oral cavity | OSCC | 1.66e-14 | 3.44e-01 | 0.1127 |
646 | BNC1 | SYSMH2 | Human | Oral cavity | OSCC | 1.98e-13 | 3.73e-01 | 0.2326 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
GO:00063563 | Oral cavity | OSCC | regulation of transcription by RNA polymerase I | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:00063601 | Oral cavity | OSCC | transcription by RNA polymerase I | 36/7305 | 55/18723 | 6.42e-05 | 5.22e-04 | 36 |
GO:00459431 | Oral cavity | OSCC | positive regulation of transcription by RNA polymerase I | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
GO:000854416 | Oral cavity | LP | epidermis development | 112/4623 | 324/18723 | 3.81e-05 | 5.61e-04 | 112 |
GO:001072014 | Oral cavity | LP | positive regulation of cell development | 93/4623 | 298/18723 | 6.07e-03 | 3.60e-02 | 93 |
GO:000854425 | Skin | cSCC | epidermis development | 131/4864 | 324/18723 | 7.38e-09 | 2.39e-07 | 131 |
GO:00063565 | Skin | cSCC | regulation of transcription by RNA polymerase I | 22/4864 | 34/18723 | 2.33e-06 | 3.77e-05 | 22 |
GO:00063603 | Skin | cSCC | transcription by RNA polymerase I | 30/4864 | 55/18723 | 6.13e-06 | 8.70e-05 | 30 |
GO:00459433 | Skin | cSCC | positive regulation of transcription by RNA polymerase I | 15/4864 | 23/18723 | 8.72e-05 | 8.21e-04 | 15 |
GO:001072016 | Skin | cSCC | positive regulation of cell development | 105/4864 | 298/18723 | 2.30e-04 | 1.89e-03 | 105 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BNC1 | SNV | Missense_Mutation | c.1349G>A | p.Cys450Tyr | p.C450Y | Q01954 | protein_coding | tolerated(1) | benign(0) | TCGA-UB-A7MD-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
BNC1 | SNV | Missense_Mutation | c.2252C>A | p.Thr751Lys | p.T751K | Q01954 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
BNC1 | SNV | Missense_Mutation | c.2755N>A | p.Leu919Ile | p.L919I | Q01954 | protein_coding | tolerated(0.21) | benign(0.112) | TCGA-05-4415-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
BNC1 | SNV | Missense_Mutation | c.2710N>A | p.Asp904Asn | p.D904N | Q01954 | protein_coding | tolerated(0.06) | benign(0.001) | TCGA-38-4632-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | gemcitabine | PD | |
BNC1 | SNV | Missense_Mutation | c.2319C>A | p.Asn773Lys | p.N773K | Q01954 | protein_coding | deleterious(0) | possibly_damaging(0.75) | TCGA-49-6745-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | SD | |
BNC1 | SNV | Missense_Mutation | c.2129N>G | p.Ala710Gly | p.A710G | Q01954 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-50-5049-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
BNC1 | SNV | Missense_Mutation | c.679N>T | p.Pro227Ser | p.P227S | Q01954 | protein_coding | tolerated(0.24) | benign(0.025) | TCGA-55-8090-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
BNC1 | SNV | Missense_Mutation | novel | c.2922C>A | p.Asn974Lys | p.N974K | Q01954 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-55-8616-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BNC1 | SNV | Missense_Mutation | novel | c.2561C>A | p.Thr854Asn | p.T854N | Q01954 | protein_coding | deleterious(0) | possibly_damaging(0.543) | TCGA-55-8616-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BNC1 | SNV | Missense_Mutation | c.1477N>A | p.Arg493Ser | p.R493S | Q01954 | protein_coding | deleterious(0.04) | possibly_damaging(0.598) | TCGA-55-A494-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |